Alios BioPharma is a biotechnology company developing novel medicines for the treatment of viral diseases. Alios has an innovative team of scientists who have discovered and developed a number of antiviral agents against viral pathogens of public health concern. Alios has developed proprietary chemical libraries of novel nucleosides, nucleoside analogs and non-nucleosides as potential therapeutics for viral infections including HCV, RSV, rhinovirus, norovirus, influenza and other emerging viruses. The nucleoside approach has an advantage over other strategies as these agents can inhibit divergent variants of many viruses resulting in therapeutics that could be used to treat existing infections as well as emerging viruses. Alios has one nucleoside analog (VX-135) in Phase 2 clinical development for the treatment of chronic hepatitis C. Under a 2011 license and collaboration agreement, the anti-HCV nucleoside analogs are being developed in collaboration with Vertex Pharmaceuticals. This collaboration has resulted in substantial cash payments to Alios and could results in additional substantial milestone payments and royalties on sales.
Alios also has nucleoside analogs that are active against RSV, a disease that infects millions of children and adults each year. Our first anti-RSV nucleoside analog entered Phase 1 clinical development in early 2013. Alios BioPharma completed a $32 million Series A financing in December of 2008 and is currently self funding through revenues received under the Vertex collaboration and license agreement.